Sunday, 22 November 2026
Venture Intelligence News

Private Equity PE-VC Fund Investments

Drug discovery-focused AI firm Peptris raises Rs.70-Cr led by IAN Alpha Fund, Speciale Invest

Source Mint (opens in a new tab)

Bengaluru-based Peptris Technologies has raised INR 70-Cr in a Series A funding round led by IAN Alpha Fund and Speciale Invest.The company has also secured an INR.86-Cr grant from the union government’s Research, Development and Innovation (RDI) Fund to advance its preclinical development pipeline.Founded in 2019, the firm operates an artificial intelligence (AI) platform to accelerate drug discovery by identifying potential molecules and targets, with a focus on rare diseases and complex proteins that have historically been considered difficult to treat. The company utilises its proprietary generative-chemistry AI to optimise small molecules and predict drug-like properties, while also exploring new indications for previously approved drugs.Peptris plans to use the new capital to transition into a discovery and development firm by bringing more development in-house and advancing four assets through preclinical stages.
Between Dec 2023 and Apr 2026, Peptris had attracted about $ 18 M from RDI Fund, IAN Fund, Speciale Invest, Tenacity Ventures, Others.For FY25, Peptris had reported about INR 2 Cr in Operating Income and about INR 1 Cr in Net loss.